Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s disease - A translational perspective

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 7, 2014, Pages 1175-1191

  Apetz, Nadine ^a   Münch, Gerald ^a   Govindaraghavan, Suresh ^b   Gyengesi, Erika ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b Network Nutrition Capitol Ingredients IMCD Australia Limited   (Australia)

Author keywords

Alzheimer s disease; Inflammation; Non steroidal anti inflammatory drugs; Plant secondary metabolites; Reactive oxygen species; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; ANTHOCYANIN; BACOSIDE; CATECHIN; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; DICLOFENAC PLUS MISOPROSTOL; ESTRADIOL; ESTROGEN; FISH OIL; FLAVONE GLYCOSIDE; HYDROXYCHLOROQUINE; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; NAPROXEN; NATURAL PRODUCT; NIMESULIDE; NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; POLYPHENOL; PREDNISONE; ROFECOXIB; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ANTI AMYLOIDOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARAGUS RACEMOSUS; ASTROCYTOSIS; BACOPA MONNIERI; BIOLOGICAL ACTIVITY; BLUEBERRY; CAMELLIA SINENSIS; CELL PROLIFERATION; COGNITION; DOWN REGULATION; GINKGO BILOBA; GLIOSIS; HUMAN; IMMUNOREACTIVITY; METABOLITE; MULTICENTER STUDY (TOPIC); NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PEROXIDATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); INFLAMMATION; PATHOPHYSIOLOGY; PHYTOTHERAPY;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84911380210     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140917110635     Document Type: Article

References (209)

1. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. J Psychiatric Res 1997; 31(6): 657-60.
2. Fang L, Gou S, Fang X, Cheng L, Fleck C. Current progresses of novel natural products and their derivatives/analogues as anti-Alzheimer candidates: an update. Minirev Med Chem 2013; 13(6): 870-87.
3. Kukull WA, Bowen JD. Dementia epidemiology. Med Clin NA 2002; 86(3): 573-90.
4. He Y, Chen Z, Gong G, Evans A. Neuronal networks in Alzheimer's disease. Neuroscientist 2009; 15(4): 333-50.
5. Wheelan L. Familial Alzheimer's Disease. Ann Hum Genet 1959; 23(3): 300-10.
6. Sánchez-Ferro Á, Benito-León J, Mitchell AJ, Bermejo-Pareja F. A review of the potential therapeutic role of statins in the treatment of Alzheimer’s disease: current research and opinion. Neuropsychiatr Dis Treat 2013; 9: 55.
7. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol 2010; 8(1): 69.
8. Sun X, Jin L, Ling P. Review of drugs for Alzheimer's disease. Drug Discov Therap 2012; 6(6): 285-90.
9. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimer's Dis 2004; 6(6): S61-74.
10. Reid AT, Evans AC. Structural networks in Alzheimer's disease. Eur Neuropsychopharmacol 2013; 23(1): 63-77.
11. Gentleman S, Roberts G. Risk factors in Alzheimer's disease. Br Med J 1992; 304(6819): 118.
12. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156(5): 445-53.
13. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat Rev Neurosci 2010; 11(5): 361-70.
14. Finder VH, Glockshuber R. Amyloid-[beta] Aggregation. Neurodegener Dis 2007; 4(1): 13-27.
15. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7(2): 161-7.
16. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010; 19(R1): R12-20.
17. Khairallah MI, Kassem LAA. Alzheimer's Disease: Current Status of Etiopathogenesis and Therapeutic Strategies. Pak J Biol Sci 2011; 14(4): 257-72.
18. Shi J, Perry G, Smith M., Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer’s disease. Neurobiol Aging 2000; 21(2): 357-61.
19. Sun X, He G, Qing H, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103(49): 18727-32.
20. Retz W, Gsell W, Munch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease. J Neural Transm Suppl 1998; 54: 221-36.
21. Munch G, Schinzel R, Loske C, et al. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105(4-5): 439-61.
22. Munoz DG, Feldman H. Causes of Alzheimer's disease. Can Med Assoc J 2000; 162(1): 65-72.
23. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156(5): 445-53.
24. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21(3): 383-421.
25. Martorana A, Bulati M, Buffa S, et al. Immunosenescence, inflammation and Alzheimer’s disease. Longev Healthspan 2012; 1(1): 1-10.
26. Rogers J, Webster S, Lue L-F, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 17(5): 681-6.
27. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002; 8(6): 529-38.
28. Townsend KP, Praticò D. Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005; 19(12): 1592-601.
29. Strohmeyer R, Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimers Dis 2001; 3(1): 131-57.
30. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Intl Med J Exp Clin Res 2007; 13(12): RA214.
31. Hanisch U-K, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-94.
32. Wood JA, Wood PL, Ryan R, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein. Brain Res 1993; 629(2): 245-52.
33. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21(2): 195-218.
34. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia. J Clin Immunol 1999; 19(4): 223-30.
35. Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, et al. Antiinflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 2001; 14(12): 1961-7.
36. Griffin W, Stanley L, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86(19): 7611-5.
37. Cacabelos R, Alvarez X, Fernandez-Novoa L, et al. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 1994; 16(2): 141.
38. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991; 285(1): 111.
39. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE 4eta; 4-associated Alzheimer's disease risk is modified by α1– antichymotrypsin polymorphism. Nat Genet 1995; 10(4): 486-8.
40. Papassotiropoulos A, Bagli M, Jessen F, et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 1999; 45(5): 666-8.
41. Nicoll JAR, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47(3): 365-8.
42. McCusker SM, Curran MD, Dynan KB, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 2001; 357(9254): 436-9.
43. Perry RT, Collins JS, Harrell LE, Acton RT, Go RCP. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to agematched controls. Am J Med Genet 2001; 105(4): 332-42.
44. Apelt J, Schliebs R. β-Amyloid-induced glial expression of both pro-and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894(1): 21-30.
45. Matsuoka Y, Picciano M, Malester B, et al. Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer’s Disease. Am J Pathol 2001; 158(4): 1345-54.
46. Sly LM, Krzesicki RF, Brashler JR, et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res Bull 2001; 56(6): 581-8.
47. Bellucci A, Westwood AJ, Ingram E, et al. Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. Am J Pathol 2004; 165(5): 1643-52.
48. Blasko I, Beer R, Bigl M, et al. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer’s disease β-secretase (BACE-1). J Neural Transm 2004; 111(4): 523-36.
49. Lee Y-J, Han SB, Nam S-Y, Oh K-W, Hong JT. Inflammation and Alzheimer’s disease. Arch Pharmacol Res 2010; 33(10): 1539-56.
50. Hawkes CA, McLaurin J, Don WC. Selective Targeting of Perivascular Macrophages for Clearance of ß-Amyloid in Cerebral Amyloid Angiopathy. Proc Natl Acad Sci USA 2009; 106(4): 1261-6.
51. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004; 58(1): 39-46.
52. Turrens JF. Superoxide Production by the Mitochondrial Respiratory Chain. Biosci Rep 1997; 17(1): 3-8.
53. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of Superoxide Production from Different Sites in the Mitochondrial Electron Transport Chain. J Biol Chem 2002; 277(47): 44784-90.
54. Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29(3–4): 222-30.
55. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408(6809): 239-47.
56. Virgilio FD. New Pathways for Reactive Oxygen Species Generation in Inflammation and Potential Novel Pharmacological Targets. Curr Pharm Des 2004; 10(14): 1647-52.
57. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010; 49(11): 1603-16.
58. Kuka S, Tatarkova Z, Kaplan P. Oxidative damage to proteins and lipids during aging. Acta Med Martin 2012; 12(1): 5-11.
59. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007; 42(2): 153-64.
60. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 676-92.
61. Nunomura A, Zhu X, Moreira P, Perry G, Smith M. Antioxidant Therapies in the Prevention and Treatment of Alzheimer Disease. Oxidative Stress and Age-Related Neurodegeneration. Oxidative Stress and Disease: CRC Press 2005; pp. 131-45.
62. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3(3): 205-14.
63. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995; 16(4): 661-74.
64. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006; 65(7): 631-41.
65. Markesbery WR. Oxidative Stress Hypothesis in Alzheimer's Disease. Free Radic Biol Med 1997; 23(1): 134-47.
66. Migliore L, Fontana I, Colognato R, et al. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 2005; 26(5): 587-95.
67. Moreira PI, Sayre LM, Zhu X, et al. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Free Radic Antioxid Prot Springer; 2010; pp. 419-34.
68. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adhesion Migr 2009; 3(1): 88-93.
69. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 1992; 140(3): 621-8.
70. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996; 149(1): 21-8.
71. Dreiseitel A, Oosterhuis B, Vukman K, et al. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol 2009; 158(8): 1942-50.
72. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987; 1(2): 89-96.
73. Vane FRSJR, Botting RM. Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs. Am J Med 1998; 104(3 Suppl): 2S-8S.
74. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Investig 2003; 112(3): 440-9.
75. Dzenko KA, Weltzien RB, Pachter JS. Suppression of Aβ-induced monocyte neurotoxicity by antiinflammatory compounds. J Neuroimmunol 1997; 80(1-2): 6-12.
76. Vane J. Towards a better aspirin. Nature 1994; 367(6460): 215.
77. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7(1): 53-8.
78. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391(6662): 79-82.
79. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists. J Neurosci 2000; 20(2): 558-67.
80. Camacho IE, Serneels L, Spittaels K, et al. Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide. J Neurosci 2004; 24(48): 10908-17.
81. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase. J Neurosci 2003; 23(30): 9796-804.
82. Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal Anti-Inflammatory Drugs Repress β-Secretase Gene Promoter Activity by the Activation of PPARγ. Proc Natl Acad Sci USA 2006; 103(2): 443-8.
83. Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin Reverses the Microglial Response to Amyloid β-Protein. Neurobiol Aging 1998; 19(3): 201-4.
84. Prosperi C, Scali C, Barba M, et al. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta (1-42)-induced brain inflammation and neuronal damage in the rat. Intl J Immunopathol Pharmacol 2004; 17(3): 317.
85. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414(6860): 212-6.
86. Lim GP, Yang F, Chu T, et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease. J Neurosci 2000; 20(15): 5709-14.
87. Yan Q, Zhang J, Liu H, et al. Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease. J Neurosci 2003; 23(20): 7504-9.
88. Lee JW, Lee YK, Yuk DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008; 5(1): 37.
89. Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain 2008; 131(3): 651-64.
90. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. J Neurosci 2002; 22(6): 2246-54.
91. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production. Nat Med 2005; 11(5): 545-50.
92. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994; 44(2): 227.
93. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995; 45(1): 51-5.
94. Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer's disease?: The Rotterdam Study. Neurology 1995; 45(8): 1441-5.
95. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E. Nonsteroidal Anti-Inflammatory Drug Use and Alzheimer's Disease: A Case-Control Study in Rochester, Minnesota, 1980 Through 1984. Mayo Clin Proc 1998; 73(10): 951-5.
96. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47(2): 425-32.
97. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.
98. In 't Veld BA, Ruitenberg A, Launer LJ, et al. Duration of nonsteroidal anti-inflammatory drug use and risk of Alzheimer's disease. The Rotterdam study. Neurobiol Aging 2000; 21(Suppl 1): 204.
99. In’t Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer’s disease. the Rotterdam study. Neurobiol Aging 1998; 19(6): 607-11.
100. Szekely CA, Green RC, Breitner JCS, et al. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008; 70(24): 2291-8.
101. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70(19): 1672-7.
102. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43(8): 1609.
103. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A doubleblind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53(1): 197.
104. Aisen P, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on alzheimer disease progression: A randomized controlled trial. J Am Med Assoc 2003; 289(21): 2819-26.
105. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002; 1(5): 279-84.
106. Aisen PS, Thal LJ, Ferris SH, et al. Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial. Curr Alzheimer Res 2008; 5(1): 73-82.
107. Thal LJ, Ferris SH, Kirby L, et al. A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology 2005; 30(6): 1204-15.
108. Zhang L, Ma Q, Yang W, et al. Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer's disease mouse model. Neuropharmacology 2013; 70(0): 200-10.
109. Kamphuis PJGH, Scheltens P. Can Nutrients Prevent or Delay Onset of Alzheimer's Disease? J Alzheimer's Dis 2010; 20(3): 765-75.
110. Weih M, Wiltfang J, Kornhuber J. Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. J Neural Transm 2007; 114(9): 1187-97.
111. Gustaw-Rothenberg K. Dietary patterns associated with Alzheimer's disease: population based study. Int J Environ Res Public Health 2009; 6(4): 1335-40.
112. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and alzheimer disease risk: A protective diet. Arch Neurol 2010; 67(6): 699-706.
113. Willis LM, Freeman L, Bickford PC, et al. Blueberry supplementation attenuates microglial activation in hippocampal intraocular grafts to aged hosts. Glia 2010; 58(6): 679-90.
114. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer’s disease. J Neurochem 2010; 112(6): 1415-30.
115. Stevenson D, Hurst R. Polyphenolic phytochemicals–just antioxidants or much more? Cell Mol Life Sci 2007; 64(22): 2900-16.
116. Lau FC, Shukitt-Hale B, Joseph JA. The beneficial effects of fruit polyphenols on brain aging. Neurobiol Aging 2005; 26(1 Suppl): 128-32.
117. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2(2): 131.
118. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease: Springer; 2007. pp. 197-212.
119. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Ind Acad Neurol 2008; 11(1): 13.
120. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Mol Targets Therap Uses Curcumin Health Dis 2007; 595: 105-25.
121. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N. Downregulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 2006; 4(1): 21-6.
122. Cho J-W, Lee K-S, Kim C-W. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alphatreated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 2007; 19(3): 469.
123. Lee HS, Jung KK, Cho JY, et al. Neuroprotective effect of curcumin is mainly mediated by blockade of microglial cell activation. Int J Pharm Sci 2007; 62(12): 937-42.
124. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009; 11(2): 241-9.
125. Yang F, Lim GP, Begum AN, et al. Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in vivo. J Biol Chem 2005; 280(7): 5892-901.
126. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21(21): 8370-7.
127. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007; 102(4): 1095-104.
128. Siddiqui R, Edwards-Smallbone J, Flynn R, Khan NA. Next generation of non-mammalian blood-brain barrier models to study parasitic infections of the central nervous system. Virulence 2012; 3(2): 159-63.
129. Narala VR, Smith M., Adapala RK, et al. Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ. Gene Ther Mol Biol 2009; 13(1): 20.
130. Begum AN, Jones MR, Lim GP, et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease. J Pharmacol Exp Therap 2008; 326(1): 196-208.
131. Ireson CR, Jones DJL, Orr S, et al. Metabolism of the Cancer Chemopreventive Agent Curcumin in Human and Rat Intestine. Cancer Epidemiol Biomarkers Prev 2002; 11(1): 105-11.
132. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects. Cancer Epidemiol Biomarkers Prev 2008; 17(6): 1411-7.
133. Jurenka JS. Anti-inflammatory Properties of Curcumin, a Major Constituent. Altern Med Rev 2009; 14(2): 141-53.
134. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Res Ther 2012; 4(5): 43.
135. Ng T-P, Chiam P-C, Lee T, et al. Curry Consumption and Cognitive Function in the Elderly. Am J Epidemiol 2006; 164(9): 898-906.
136. Ganguli M, Chandra V, Kamboh M, et al. Apolipoprotein e polymorphism and alzheimer disease: The indo-us cross-national dementia study. Arch Neurol 2000; 57(6): 824-30.
137. Baum L, Lam CWK, Cheung SK-K, et al. Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease. J Clin Psychopharmacol 2008; 28(1): 110-3.
138. Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebocontrolled trial. J Altern Compl Med 2008; 14(6): 707-13.
139. Saini N, Singh D, Sandhir R. Neuroprotective Effects of Bacopa monnieri in Experimental Model of Dementia. Neurochem Res 2012; 37(9): 1928-37.
140. Garai S, Mahato SB, Ohtani K, Yamasaki K. Dammarane-type triterpenoid saponins from Bacopa monniera. Phytochemistry 1996; 42(3): 815-20.
141. Deepak M, Sangli GK, Arun PC, Amit A. Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLC. Phytochem Anal 2005; 16(1): 24-9.
142. Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res 2008; 22(12): 1629-34.
143. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 2001; 156(4): 481-4.
144. Viji V, Helen A. Inhibition of lipoxygenases and cyclooxygenase-2 enzymes by extracts isolated from Bacopa monniera (L.) Wettst. J Ethnopharmacol 2008; 118(2): 305-11.
145. Williams R, Munch G, Gyengesi E, Bennett L. Bacopamonnieri (L.) exerts anti-inflammatory effects on cells of the innate immune system in vitro. Food Func 2014; 5(3): 517-20.
146. Russo A, Borrelli F, Campisi A, et al. Nitric oxide-related toxicity in cultured astrocytes: effect of Bacopa monniera. Life Sci 2003; 73(12): 1517-26.
147. Channa S, Dar A, Anjum S, Yaqoob M, Atta ur R. Antiinflammatory activity of Bacopa monniera in rodents. J Ethnopharmacol 2006; 104(1-2): 286-9.
148. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monnieri on betaamyloid-induced cell death in primary cortical culture. J Ethnopharmacol 2008; 120(1): 112-7.
149. Holcomb LA, Dhanasekaran M, Hitt AR, et al. Bacopa monniera extract reduces amyloid levels in PSAPP mice. J Alzheimer's Dis 2006; 9(3): 243-51.
150. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol 2010; 127(1): 26-31.
151. Jain P, Khanna N, Trehan N, Pendse V, Godhwani J. Antiinflammatory effects of an Ayurvedic preparation, Brahmi Rasayan, in rodents. Ind J Exp Biol 1994; 32(9): 633.
152. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 2004; 15(9): 506-16.
153. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Therap 2008; 14(4): 352-65.
154. Choi Y-T, Jung C-H, Lee S-R, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates β-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001; 70(5): 603-14.
155. Cabrera C, Artacho R, Giménez R. Beneficial Effects of Green Tea - A Review. J Am Coll Nutr 2006; 25(2): 79-99.
156. Rezai-Zadeh K, Shytle D, Sun N, et al. Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice. J Neurosci 2005; 25(38): 8807-14.
157. Lee JW, Lee YK, Ban JO, et al. Green Tea (-)-Epigallocatechin-3-Gallate Inhibits β-Amyloid-Induced Cognitive Dysfunction through Modification of Secretase Activity via Inhibition of ERK and NF-κB Pathways in Mice. J Nutr 2009; 139(10): 1987-93.
158. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002; 33(8): 1097-105.
159. Lee SY, Lee JW, Lee H, et al. Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Mol Brain Res 2005; 140(1-2): 45-54.
160. Haque AM, Hashimoto M, Katakura M, et al. Long-Term Administration of Green Tea Catechins Improves Spatial Cognition Learning Ability in Rats. J Nutr 2006; 136(4): 1043-7.
161. Katiyar SK, Matsui MS, Elmets CA, Mukhtar H. Polyphenolic Antioxidant (-)-Epigallocatechin-3-Gallate from Green Tea Reduces UVB-lnduced Inflammatory Responses and Infiltration of Leukocytes in Human Skin. Photochem Photobiol 1999; 69(2): 148-53.
162. Kuriyama S, Hozawa A, Ohmori K, et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project. Am J Clin Nutr 2006; 83(2): 355-61.
163. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci 2011; 12(9): 5592-603.
164. Timell T. Ultrastructure of compression wood in Ginkgo biloba. Wood Sci Technol 1978; 12(2): 89-103.
165. Yoshikawa T, Naito Y, Kondo M. Ginkgo biloba leaf extract: review of biological actions and clinical applications. Antioxid Redox Signal 1999; 1(4): 469-80.
166. Clostre F, Ed. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000. Ann Pharm Fran 1999; 57(Suppl 1): 158-188.
167. Yves C. Ginkgo biloba Extract and Alzheimer's Disease. Oxidative Stress and Age-Related Neurodegeneration. Oxidative Stress and Disease: CRC Press; 2005; pp. 43-58.
168. Wadsworth TL, Koop DR. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. Chem Biol Inter 2001; 137(1): 43-58.
169. Ilieva I, Ohgami K, Shiratori K, et al. The effects of Ginkgo biloba extract on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res 2004; 79(2): 181-7.
170. Kwak W-J, Han CK, Son KH, et al. Effects of Ginkgetin from Ginkgo biloba leaves on cyclooxygenases and in vivo skin inflammation. Plant Med 2002; 68(04): 316-21.
171. Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimer's Dis 2003; 5(4): 287-300.
172. Bastianetto S, Ramassamy C, Doré S, et al. The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur J Neurosci 2000; 12(6): 1882-90.
173. Augustin S, Rimbach G, Augustin K, et al. Effect of a short-and long-term treatment with Ginkgo biloba extract on Amyloid Precursor Protein Levels in a transgenic mouse model relevant to Alzheimer’s disease. Arch Biochem Biophys 2009; 481(2): 177-82.
174. Stackman RW, Eckenstein F, Frei B, et al. Prevention of agerelated spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 2003; 184(1): 510-20.
175. Ching-Hsiang L, Chiao-Wen H, Nan-Fu C, et al. In vivo effects of Ginkgo biloba extract on interleukin-6 cytokine levels in patients with neurological disorders. Ind J Pharmacol 2012; 44(1): 118.
176. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Phytomedicine 1997; 4(1): 3-13.
177. Maurer K, Ihl R, Dierks T, Frölich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatric Res 1997; 31(6): 645-55.
178. Le Bars P, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. J Am Med Assoc 1997; 278(16): 1327-32.
179. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimers type. Curr Alzheimer Res 2005; 2(5): 541-51.
180. Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JPE. Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action. Nutrients 2010; 2(11): 1106-31.
181. Routray W, Orsat V. Blueberries and Their Anthocyanins: Factors affecting biosynthesis and properties. Compr Rev Food Sci Food Safety 2011; 10(6): 303-20.
182. Giacalone M, Di Sacco F, Traupe I, et al. Antioxidant and neuroprotective properties of blueberry polyphenols: a critical review. Nutr Neurosci 2011; 14(3): 119-25.
183. Lau FC, Bielinski DF, Joseph JA. Inhibitory effects of blueberry extract on the production of inflammatory mediators in lipopolysaccharide-activated BV2 microglia. J Neurosci Res 2007; 85(5): 1010-7.
184. Lau FC, Joseph JA, McDonald JE, Kalt W. Attenuation of iNOS and COX2 by blueberry polyphenols is mediated through the suppression of NF-κB activation. J Funct Foods 2009; 1(3): 274-83.
185. Han G, Li C, Mazza G, Yang X. Effect of anthocyanin rich fruit extract on PGE2 produced by endothelial cells. J Hyg Res 2005; 34(5): 581.
186. Zhu Y, Bickford PC, Sanberg P, Giunta B, Tan J. Blueberry Opposes β-Amyloid Peptide-Induced Microglial Activation Via Inhibition of p44/42 Mitogen-Activation Protein Kinase. Rejuven Res 2008; 11(5): 891-901.
187. Xie C, Kang J, Ferguson ME, et al. Blueberries reduce proinflammatory cytokine TNF-α and IL-6 production in mouse macrophages by inhibiting NF-κB activation and the MAPK pathway. Mol Nutr Food Res 2011; 55(10): 1587-91.
188. Goyarzu P, Malin DH, Lau FC, et al. Blueberry Supplemented Diet: Effects on Object Recognition Memory and Nuclear Factorkappa B Levels in Aged Rats. Nutr Neurosci 2004; 7(2): 75-83.
189. Torri E, Lemos M, Caliari V, et al. Anti-inflammatory and antinociceptive properties of blueberry extract (Vaccinium corymbosum). J Pharm Pharmacol 2007; 59(4): 591-6.
190. Krikorian R, Shidler MD, Nash TA, et al. Blueberry Supplementation Improves Memory in Older Adults. J Agric Food Chem 2010; 58(7): 3996-4000.
191. Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in human nutrition. J Am Dietetic Assoc 1991; 91: 331.
192. Watkins BA, Li Y, Lippman HE, Seifert MF. Omega-3 Polyunsaturated Fatty Acids and Skeletal Health. Exp Biol Med 2001; 226(6): 485-97.
193. Ruxton CHS, Reed SC, Simpson MJA, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Human Nutr Diet 2004; 17(5): 449-59.
194. Simopoulos AP. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med 2008; 233(6): 674-88.
195. Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease. Clin Interv Aging 2010; 5: 45.
196. Narayanan BA, Narayanan NK, Simi B, Reddy BS. Modulation of Inducible Nitric Oxide Synthase and Related Proinflammatory Genes by the Omega-3 Fatty Acid Docosahexaenoic Acid in Human Colon Cancer Cells. Cancer Res 2003; 63(5): 972-9.
197. Li H, Ruan XZ, Powis SH, et al. EPA and DHA reduce LPSinduced inflammation responses in HK-2 cells: Evidence for a PPAR-γ–dependent mechanism. Kidney Int 2005; 67(3): 867-74.
198. Dyall SC, Michael GJ, Michael-Titus AT. Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J Neurosci Res 2010; 88(10): 2091-102.
199. Lim GP, Calon F, Morihara T, et al. A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model. J Neurosci 2005; 25(12): 3032-40.
200. Hashimoto M, Hossain S, Shimada T, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002; 81(5): 1084-91.
201. Mori T, Beilin L. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004; 6(6): 461-7.
202. Calder PC. n- 3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83(6): S1505-19S.
203. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991; 121(4): 547-55.
204. Morris M, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident alzheimer disease. Arch Neurol 2003; 60(7): 940-6.
205. Laurin D, Verreault R, Lindsay J, Dewailly É, Holub BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimer's Dis 2003; 5(4): 315-22.
206. Schaefer EJ, Bongard V. Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and alzheimer disease: The framingham heart study. Arch Neurol 2006; 63(11): 1545-50.
207. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. {omega}-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63(10): 1402.
208. Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23(2): 161-9.
209. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009; 5(3): 140-52.